| pubmed-article:10716329 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10716329 | lifeskim:mentions | umls-concept:C0034603 | lld:lifeskim |
| pubmed-article:10716329 | lifeskim:mentions | umls-concept:C1504389 | lld:lifeskim |
| pubmed-article:10716329 | lifeskim:mentions | umls-concept:C0009647 | lld:lifeskim |
| pubmed-article:10716329 | lifeskim:mentions | umls-concept:C0085101 | lld:lifeskim |
| pubmed-article:10716329 | lifeskim:mentions | umls-concept:C1705241 | lld:lifeskim |
| pubmed-article:10716329 | lifeskim:mentions | umls-concept:C1705242 | lld:lifeskim |
| pubmed-article:10716329 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:10716329 | pubmed:dateCreated | 2000-4-7 | lld:pubmed |
| pubmed-article:10716329 | pubmed:abstractText | A new concept is the intensification of preparative regimens for patients with advanced leukemia using monoclonal antibodies (MAbs) with an affinity for beta emitter-labeled bone marrow. 188Re is a high-energy beta emitter that has therapeutic promise. Our first aim was to clarify whether the therapeutic application of 188Re-MAb against nonspecific cross-reacting antigen 95 (NCA-95) can be predicted from biokinetic data derived from 99mTc-labeled NCA-95. Our second aim was to show that a radiation absorbed dose of > or =12 Gy in the bone marrow can be achieved using 188Re-MAb. | lld:pubmed |
| pubmed-article:10716329 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10716329 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10716329 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10716329 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10716329 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10716329 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10716329 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10716329 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10716329 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10716329 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10716329 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:10716329 | pubmed:issn | 0161-5505 | lld:pubmed |
| pubmed-article:10716329 | pubmed:author | pubmed-author:SeitzUU | lld:pubmed |
| pubmed-article:10716329 | pubmed:author | pubmed-author:BergmannLL | lld:pubmed |
| pubmed-article:10716329 | pubmed:author | pubmed-author:DunckerCC | lld:pubmed |
| pubmed-article:10716329 | pubmed:author | pubmed-author:ReskeS NSN | lld:pubmed |
| pubmed-article:10716329 | pubmed:author | pubmed-author:BunjesDD | lld:pubmed |
| pubmed-article:10716329 | pubmed:author | pubmed-author:KotzerkeJJ | lld:pubmed |
| pubmed-article:10716329 | pubmed:author | pubmed-author:RentschlerMM | lld:pubmed |
| pubmed-article:10716329 | pubmed:author | pubmed-author:GlattingGG | lld:pubmed |
| pubmed-article:10716329 | pubmed:author | pubmed-author:NeumaierBB | lld:pubmed |
| pubmed-article:10716329 | pubmed:author | pubmed-author:DohrDD | lld:pubmed |
| pubmed-article:10716329 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10716329 | pubmed:volume | 41 | lld:pubmed |
| pubmed-article:10716329 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10716329 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10716329 | pubmed:pagination | 531-7 | lld:pubmed |
| pubmed-article:10716329 | pubmed:dateRevised | 2005-11-21 | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:meshHeading | pubmed-meshheading:10716329... | lld:pubmed |
| pubmed-article:10716329 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10716329 | pubmed:articleTitle | Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs. | lld:pubmed |
| pubmed-article:10716329 | pubmed:affiliation | Department of Nuclear Medicine, University Ulm, Germany. | lld:pubmed |
| pubmed-article:10716329 | pubmed:publicationType | Journal Article | lld:pubmed |
